Crown Bioscience: First Clinical Candidate Developed Using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428006002/en/
The study was the result of work by an international consortium, SuppresSTEM which included Crown Bioscience (previously OcellO B.V.) and HUB. Crown Bioscience and HUB led the design of the experiments which were executed using the high content screening platform from Crown Bioscience using HUB Organoids. These studies enabled the discrimination of antibodies that were active against a broad range of mutational profiles and tumor subtypes, with hit validation and mechanism of action studies that enabled selection of optimally performing antibodies. Follow up in vivo studies in matched patient-derived xenograft (PDX) models were also performed by Crown Bioscience.
The work, spanning about five years, involved Crown Bioscience screening a library of hundreds of bispecific antibodies and rescreening of ‘hits’ in a panel of patient-derived colorectal cancer organoids and matching normal organoids, that were developed by HUB and characterized by HUB and other consortium members. Organoids are stem cell-derived mini-organs developed from any patient resection or biopsy tissue that can be grown in the laboratory, which can be applied like conventional cell lines in early drug discovery.
“This is the first study that has used organoids exclusively for cell-based compound screening and characterization, leading to a compound entering clinical trials. This is a truly remarkable achievement that demonstrates the validity and application of HUB Organoids in high throughput screening and oncology drug discovery”, said Leo Price PhD, Senior Vice President In Vitro Oncology at Crown Bioscience.
“This groundbreaking work demonstrates the power and potential of HUB Organoid Technology”, commented Rob Vries PhD, CEO at HUB. “Using organoids, we were able to accelerate the timeline from initial discovery to clinical trials to about five years.”
Nature Cancer is a journal which covers the latest, most significant cancer-related advances across the life, physical, applied and social sciences, focusing on new approaches for the development and delivery of diagnostics and therapeutics, as well as clinical studies regarding cancer diagnosis, treatment and prevention.
Read the full paper here: https://go.nature.com/3LhuAAy
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to hold a commercial license to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: https://www.crownbio.com.
About HUB
HUB Organoids (HUB) is the global leader in the field of adult stem cell-derived organoid. The technology invented by HUB’s scientists in the lab of world-renowned Prof. Hans Clevers represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides drug screening services and access to its living organoid biobanks.
About SupresStem
The SuppresSTEM consortium was funded by EU FP7 and involved collaborative work by companies including OcellO B.V./Crown Bioscience, HUB Organoids, and Merus N.V., and international research institutions including the Hubrecht Institute, IRB Barcelona and the Sanger Institute. The Vall d'Hebron Institute of Oncology (VHIO), the Catalan Institute of Oncology and the company Xenopad also collaborated in data for this publication. The consortium set out to develop novel antibody-based therapeutics targeting cancer stem cells for the treatment of colorectal cancer as well as patient-derived organoid-based screening tools to aid drug discovery.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428006002/en/
Contact information
Media Enquiries
Crown Bioscience
Louise Stenson
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Malaysia Digital Economy Corporation and Ant International Deepen Partnership to Accelerate Digitalisation of MSMEs Across Malaysia3.12.2025 08:00:00 EET | Press release
The Malaysia Digital Economy Corporation (MDEC) and Ant International are strengthening their partnership to accelerate the digital transformation of micro, small and medium enterprises (MSMEs) nationwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202701220/en/ (L-R) Chen Leiming, Senior Vice President & Chief Sustainability Officer of Ant International; Ir. Wan Murdani Wan Mohamad, Vice President of Digital Adoption, MDEC; Ian Cheong, CEO of EPOS In a newly established Memorandum of Understanding (MoU), Ant International will empower local MSMEs through EPOS, the all-in-one SME transformation platform of Ant International’s Antom, offering a comprehensive suite of digitalisation solutions. MDEC will support the programme by engaging the MSME community, industry associations, and ecosystem partners to drive broad-based digital adoption across the country. This builds on MDEC’s ongoing collaboration with Ant Internati
Hyatt Advances Luxury Brand Focus With New Leadership and Planned Global Expansion in 20263.12.2025 08:00:00 EET | Press release
Hyatt Hotels Corporation (NYSE: H) today announced at ILTM Cannes the next chapter of Hyatt’s luxury journey, unveiling strengthened leadership with the appointment of Tamara Lohan as Global Brand Leader – Luxury on an interim basis and previewing a remarkable pipeline of luxury openings set for 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202423660/en/ Tamara Lohan, Global Brand Leader – Luxury, Hyatt “Hyatt’s momentum in luxury continues to accelerate, powered by our insights-driven development strategy and commitment to delivering deeply resonant guest experiences,” said Mark Hoplamazian, President and Chief Executive Officer, Hyatt. “Tamara brings world-class luxury expertise, and her leadership will further strengthen our ability to differentiate our luxury brands while growing with intent in the markets our guests and owners value most.” Lohan joined Hyatt in 2023 through the acquisition of Mr & Mrs Smith, t
Kioxia and Google Collaborate to Boost Clean Energy Use in Japan3.12.2025 04:30:00 EET | Press release
As part of its commitment towards a more sustainable future, Kioxia Corporation (“Kioxia”) today announced a collaborative initiative with Google LLC (“Google”) to boost its use of the clean electricity generated by a hydropower retrofit project in Japan's Chubu region. This project, owned by the Chubu Electric Power group, is expected to increase annual clean energy generation, contributing to the decarbonization of the grid and supporting both companies' net-zero efforts. Kioxia, a leader in memory solutions, has begun offtake of its portion of the hydropower project's electricity, which is expected to reach 160 gigawatt-hour (GWh) per year (enough to power about 40,000 Japanese homes). This move directly supports Kioxia's goals of sourcing 100% renewable energy for use in its own business activity by fiscal year (“FY”) 2040 and achieving net-zero greenhouse gas emissions by FY2050. Kioxia’s hydropower offtake, which provides “round-the-clock” clean power, also helps reduce Google's
NIKE, Inc. Announces Senior Leadership Changes to Accelerate “Win Now” Actions2.12.2025 23:59:00 EET | Press release
NIKE, Inc. (NYSE:NKE) today shared the following note with employees regarding changes to its Senior Leadership Team. // Team, I’d like to share some important changes to our Senior Leadership Team (SLT) that further remove layers and continue to bring us closer to athletes* and the marketplace. We’re establishing the role of EVP, Chief Operating Officer (COO), reporting to me, to better connect our operations and integrate technology more seamlessly into our sport offense. Venkatesh Alagirisamy (“Venky”), currently Chief Supply Chain Officer and a nearly 20-year Nike veteran, will take on this role effective December 8. Venky will lead Technology, in addition to his existing responsibilities leading Supply Chain, Planning, Operations, Manufacturing and Sustainability. He and his team will now be able to look end-to-end to ensure technology is fully integrated across the company and into how we create, plan, make, deliver and sell our world-class innovations across our three iconic bra
NetApp Collaborates with AWS to bring Enterprise Data to AWS AI Services2.12.2025 20:30:00 EET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced a new capability that enables enterprises to make their workflows simpler and more efficient by connecting Amazon Web Services (AWS) AI and Analytics services directly with their NetApp data both in the cloud and on-premises. Amazon S3 Access Points for Amazon FSx for NetApp ONTAP® enable customers to accelerate AI and analytics projects by allowing FSx for ONTAP-resident file data to be accessed via the S3 API by AWS's extensive portfolio of AI/ML and analytics services—all while the data remains in place and is fully accessible for read / write via file protocols. “By connecting FSx for ONTAP data natively to AWS's wide range of AI, ML, and analytics services, the new integration with Amazon S3 Access Points unleashes the potential to connect to more than 100 exabytes of enterprise data stored on NetApp systems for transformative use cases like generative AI and analytics uses cases built on AWS,” sa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom